Department of Developmental Biology and Cancer Research, Institute for Medical Research Israel-Canada, Hadassah Medical School, Hebrew University, P.O. Box 12272, Jerusalem 91120, Israel.
Department of Immunology and Cancer Research and Department of Pathology, Institute for Medical Research Israel-Canada, Hadassah Medical School, Hebrew University, Jerusalem 91120, Israel.
Cells. 2022 Mar 10;11(6):949. doi: 10.3390/cells11060949.
Vav1 is normally and exclusively expressed in the hematopoietic system where it functions as a specific GDP/GTP nucleotide exchange factor (GEF), firmly regulated by tyrosine phosphorylation. Mutations and overexpression of Vav1 in hematopoietic malignancies, and in human cancers of various histologic origins, are well documented. To reveal whether overexpression of Vav1 in different tissues suffices for promoting the development of malignant lesions, we expressed Vav1 in transgenic mice by using the ubiquitous ROSA26 promoter (Rosa Vav1). We detected Vav1 expression in epithelial tissues of various organs including pancreas, liver, and lung. While carcinomas did not develop in these organs, surprisingly, we noticed the development of B-cell lymphomas. Rac1-GTP levels did not change in tissues from Rosa Vav1 mice expressing the transgenic Vav1, while ERK phosphorylation increased in the lymphomas, suggesting that signaling pathways are evoked. One of the growth factors analyzed by us as a suspect candidate to mediate paracrine stimulation in the lymphocytes was CSF-1, which was highly expressed in the epithelial compartment of Rosa Vav1 mice. The expression of its specific receptor, CSF-1R, was found to be highly expressed in the B-cell lymphomas. Taken together, our results suggest a potential cross-talk between epithelial cells expressing Vav1, that secrete CSF-1, and the lymphocytes that express CSF-1R, thus leading to the generation of B-cell lymphomas. Our findings provide a novel mechanism by which Vav1 contributes to tumor propagation.
Vav1 通常仅在造血系统中表达,在造血系统中作为特定的 GDP/GTP 核苷酸交换因子 (GEF) 发挥作用,其活性受到酪氨酸磷酸化的严格调节。Vav1 在造血恶性肿瘤以及各种组织起源的人类癌症中的突变和过表达已有充分的文献记载。为了揭示造血组织以外的 Vav1 过表达是否足以促进恶性病变的发展,我们使用广泛表达的 ROSA26 启动子(Rosa Vav1)在转基因小鼠中表达 Vav1。我们在包括胰腺、肝脏和肺在内的各种器官的上皮组织中检测到 Vav1 的表达。尽管这些器官没有发展成癌,但令人惊讶的是,我们注意到 B 细胞淋巴瘤的发展。在表达转基因 Vav1 的 Rosa Vav1 小鼠的组织中,Rac1-GTP 水平没有变化,而 ERK 磷酸化在淋巴瘤中增加,这表明信号通路被激活。我们分析的一种作为旁分泌刺激淋巴细胞的嫌疑候选生长因子是 CSF-1,它在上皮细胞中高度表达 Rosa Vav1 小鼠。发现其特异性受体 CSF-1R 在 B 细胞淋巴瘤中高度表达。总之,我们的结果表明,表达 Vav1 的上皮细胞与表达 CSF-1R 的淋巴细胞之间存在潜在的串扰,从而导致 B 细胞淋巴瘤的产生。我们的研究结果提供了一种新的机制,Vav1 通过该机制促进肿瘤的传播。